Shanliang Tech Secures Nearly RMB 100 Million Series A Funding to Accelerate Commercialization of Fully Automated Ultra-Multiplex PCR System

VCBeat (WeChat: vcbeat) has learned that Shenzhen Shanliang Technology Co., Ltd. (hereinafter referred to as “Shanliang Technology”), an emerging player in molecular diagnostics, has recently completed a Series A financing round of nearly RMB 100 million. The round was led by Fosun RZ Capital (Shenzhen) Power Tech Angel Fund, with participation from YuanBio Venture Capital, and additional support from existing shareholder Zhejiang United Investment Group.

Shenzhen Shanliang Technology Co., Ltd., founded in 2018, is dedicated to providing fully automated molecular diagnostic solutions. Its core team members have accumulated extensive industry experience over many years, with profound expertise in instruments, microfluidic chips, reagents, and clinical applications. Leveraging multidimensional, multidisciplinary integrated innovation and its proprietary microarray-quantitative fluorescence nucleic acid amplification (microarray-qPCR) technology, the company has successfully developed an ultra-multiplex quantitative fluorescent PCR platform featuring a “sample-in, result-out” workflow.

Shanliang Technology’s FDx-1000, an instant multiplex quantitative molecular diagnostics platform, enables fully enclosed, one-touch “sample-in, result-out” rapid multiplex nucleic acid testing. It is widely applicable in pathogen detection for infectious and infection-related diseases, companion diagnostics, medication guidance, identity verification, environmental monitoring, food safety, and other fields.

Yue Min, CEO of Shanliang Technologystated that "sample-in, result-out" molecular diagnostic platforms are extremely scarce worldwide, a shortage that became particularly evident during the COVID-19 pandemic. Leveraging years of accumulated expertise in instrumentation, microfluidic chips, reagents, and clinical applications, the team at Shenzhen Shanliang Technology Co., Ltd. has successfully developed a point-of-care multiplex quantitative molecular diagnostic platform featuring multiple advantages, including convenience, contamination-free operation, and full automation. This round of financing will accelerate the R&D, regulatory registration, and technology transfer for mass production of its automated molecular diagnostic product series, while advancing commercialization efforts. We aim to fundamentally transform the complex requirements and cumbersome processes associated with traditional molecular diagnostics, promote the widespread adoption of precision molecular diagnostics in primary healthcare institutions, and foster the robust development of China’s broader health industry.

Hou Jun, Managing Director of Investment at Fosun RZ CapitalShanliang Technology has assembled a team of experts in microfluidics and molecular biology from China and the United States, boasting globalized teams and technical capabilities. Recently, it has achieved technological breakthroughs in multiplex quantitative and low-cost POCT molecular diagnostics. In the post-pandemic era, the routine and decentralized adoption of molecular diagnostics will be a long-term trend, with hospitals at all levels experiencing a sustained increase in demand for point-of-care testing and precision medicine. We look forward to Shanliang Technology and Fosun jointly promoting the widespread adoption and application of POCT molecular diagnostics to benefit a broader population.

Chen Hong, Executive General Manager of Investment at Fosun Creative CapitalIntroduction: We place great value on the founding core team of Shanliang Technology, which possesses both a global perspective and resources, as well as extensive experience in local Chinese production and operations. This unique combination not only integrates the world’s most advanced multiplex molecular diagnostic (POCT) technologies with the Chinese healthcare market but also leverages China’s manufacturing advantages to simultaneously expand the global molecular POCT market. By truly harnessing Chinese momentum to connect with global resources, we provide a personalized, diversified, and patient-centric C2M diagnostic model.

Dr. Lin Yi, Managing Partner at YuanBio Venture CapitalIt is believed that "sample-in, result-out" molecular diagnostic products represent an inevitable trend in industry development and entail high technical barriers. The team at Shenzhen Shanliang Technology Co., Ltd. possesses extensive experience in molecular diagnostic instruments, microfluidic chips, reagents, and clinical applications. The company’s point-of-care multiplex quantitative molecular diagnostic platform has broad application scenarios, ranging from clinical departments in tertiary hospitals to primary healthcare institutions. We look forward to the company establishing its foothold in China and expanding globally, providing physicians and patients with superior molecular diagnostic product solutions.

Yuan Huagang, Partner at Zhejiang United Investment GroupIt was stated that the point-of-care testing (POCT) transformation in the field of molecular diagnostics is a prevailing trend, with companies continuously evolving their products and technologies toward greater portability, efficiency, and precision. This is particularly critical for detecting the ever-changing landscape of infectious pathogens, which demands diagnostic methods that are faster, more agile, multiplexed, and cost-effective. Shenzhen Shanliang Technology Co., Ltd. has entered the POCT market for infectious diseases and developed highly productized solutions, while also continuously expanding the feasibility of its platform for other disease areas. Backed by a founding team with an average of 20 years of technical expertise in life sciences, microfluidics, and electromechanical automation, the company has steadily enhanced its R&D, production, and management capabilities for in vitro diagnostic applications, establishing a proprietary portfolio of patents in multiplexed point-of-care molecular diagnostic platform technologies. Unlike the cumbersome and complex processes of traditional molecular diagnostics, the company’s POCT molecular diagnostic products demonstrate superior performance in terms of turnaround time, cost, and multiplexing capacity. Zhejiang United Investment Group/IoT Fund looks forward to partnering with Shenzhen Shanliang Technology Co., Ltd. to advance the development of precise diagnostics, thereby benefiting primary healthcare industries in China and worldwide.

Fosun Chuangfu is an equity investment management company under Fosun Group and a leading dual-currency private equity investment firm in the industry. As a top-tier private fund manager in China, Fosun Chuangfu provides high-quality equity investment management services to investors such as renowned domestic and international family funds, pension funds, insurance companies, listed companies, large institutional investors, and high-net-worth individuals. Leveraging its strong investment capabilities, high-caliber post-investment services, and Fosun’s robust global industrial integration resources, Fosun Chuangfu empowers its portfolio companies with business resources and deep industry expertise, helping them achieve long-term value appreciation and sustainable development.

Since its establishment in 2007, Fosun Capital has, over the past fourteen years, initiated and managed assets including funds of funds, private equity investment funds, industrial funds for listed companies, and other types of equity investment funds. Fosun Capital focuses on four key sectors: new materials and intelligent manufacturing, digital economy and new consumption, healthcare, and next-generation information technology. It has invested in more than 100 companies, with nearly 50 achieving successful exits through domestic or overseas listings and other channels.

YuanBio Venture Capital is an investment firm focused on the early and growth stages of the healthcare sector. Headquartered in Suzhou BioBAY, it maintains a global reach. To date, YuanBio has invested in over 140 outstanding companies in the life and health sectors, covering four key areas: novel drug development, medical devices, in vitro diagnostics (IVD) and precision medicine, as well as healthcare services. The firm has achieved substantial investment returns, with 13 of its portfolio companies listed on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanBio Venture Capital has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and as one of the most active healthcare investment institutions in China. By bringing together seasoned professional investors and a team of world-class scientific advisors, YuanBio possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and beyond. Leveraging its professionalism, focus, and abundant industry resources, YuanBio is committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.

Zhejiang United Investment Group (hereinafter referred to as “Zhejiang United Investment” or the “Company”) is a large-scale joint-stock industrial-financial investment company that aggregates capital and financial resources from outstanding private enterprises in Zhejiang Province. Spearheaded by the Zhejiang Provincial Federation of Industry and Commerce and guided by the Zhejiang Provincial Financial Affairs Office, the Company was jointly established in April 2015 by eight leading private enterprises and institutions in Zhejiang, pioneering a new model for the clustered development and cross-sector operations of private capital in the investment sector within the province. The initial registered capital amounted to RMB 5 billion.

Zhejiang United Investment Group (ZUIG) and its IoT Fund have invested over RMB 4 billion in the healthcare sector, with deep strategic layouts in sub-sectors including biological products, medical diagnostics, innovative drugs, drug R&D and AI-driven medicinal chemistry, surgical robots, and minimally invasive interventional procedures.